Citicoline is not protective in experimental models of Huntington's disease.
We have evaluated the neuroprotective effects of citicoline in relevant phenotypic models of Huntington's disease induced by either the mitochondrial inhibitor 3-nitropropionic acid or the N-methyl-D-aspartate agonist quinolinic acid, which, respectively, reproduce the metabolic defect or the excitotoxicity seen in the disease. We found that citicoline failed to reverse behavioural and histological alterations induced by both neurotoxins. In addition, citicoline did not reduce PC12 cell death induced by the expression of an N-terminal fragment of mutated Huntingtin. Altogether, our results suggest that citicoline is not a potential therapeutic agent for the treatment of Huntington's disease.
Mievis
Stéphane
S
IRIBHM, University of Brussels, ULB-Erasme, Brussels, Belgium.
Levivier
Marc
M
Vassart
Gilbert
G
Brotchi
Jacques
J
Ledent
Catherine
C
Blum
David
D
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003566:Cytidine Diphosphate Choline / Q000008:administration & dosage*; D004195:Disease Models, Animal; D006816:Huntington Disease / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D018696:Neuroprotective Agents / Q000008:administration & dosage; D018697:Nootropic Agents; D051381:Rats; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D018697:Nootropic Agents; D003566:Cytidine Diphosphate Choline